Spinal Muscular Atrophy Type 1 Latest Advances

Autism spectrum disorder in children with spinal muscular atrophy type 1: Case series.

Journal: Developmental medicine and child neurology

Published: April 09, 2026

Challenges in assessing autism spectrum disorder in spinal muscular atrophy type 1.

Journal: Developmental medicine and child neurology

Published: February 01, 2026

Swallowing assessment in spinal muscular atrophy type 1: a real-world study of dysphagia in children receiving disease-modifying therapies.

Journal: Neuromuscular disorders : NMD

Published: January 27, 2026

Fusionless spinal surgery in children with spinal muscular atrophy type 1 with bipolar system: a preliminary communication.

Journal: Journal of pediatric orthopedics. Part B

Published: January 22, 2026

285th ENMC international workshop: SMN-associated neurodevelopmental disorder: type 1 spinal muscular atrophy and the brain, 31st January - 2nd February 2025, Hoofddorp, The Netherlands.

Journal: Neuromuscular disorders : NMD

Published: December 02, 2025

Longitudinal assessment of respiratory status utilising the amended Great Ormond Street Respiratory Score in treated spinal muscular atrophy type 1 children.

Journal: Neuromuscular disorders : NMD

Published: October 21, 2025

Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.

Journal: JAMA network open

Published: October 08, 2025

Elexacaftor/Tezacaftor/Ivacaftor Therapy in a Child With Cystic Fibrosis and Type 1 Spinal Muscular Atrophy.

Journal: Pediatric pulmonology

Published: October 07, 2025

Autism spectrum disorder in children with spinal muscular atrophy type 1: Case series.

Journal: Developmental medicine and child neurology

Published: September 25, 2025

A Retrospective Cohort Study of Nutrition Outcomes in Children With Spinal Muscular Atrophy Type 1 and 2 Treated With Disease Modifying Therapies.

Journal: Muscle & nerve

Published: September 17, 2025

Adult Survival in SMA Type 1: A 23-Year Journey With Home Ventilation and Multidisciplinary Support.

Journal: Clinical case reports

Published: August 28, 2025

Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye.

Journal: Muscle & nerve

Published: July 07, 2025

Spinal Muscular Atrophy Type 1 Latest Advances

Find the Latest Research About Spinal Muscular Atrophy Type 1

Autism spectrum disorder in children with spinal muscular atrophy type 1: Case series.

Autism spectrum disorder in children with spinal muscular atrophy type 1: Case series.

Challenges in assessing autism spectrum disorder in spinal muscular atrophy type 1.

Challenges in assessing autism spectrum disorder in spinal muscular atrophy type 1.

Swallowing assessment in spinal muscular atrophy type 1: a real-world study of dysphagia in children receiving disease-modifying therapies.

Swallowing assessment in spinal muscular atrophy type 1: a real-world study of dysphagia in children receiving disease-modifying therapies.

Fusionless spinal surgery in children with spinal muscular atrophy type 1 with bipolar system: a preliminary communication.

Fusionless spinal surgery in children with spinal muscular atrophy type 1 with bipolar system: a preliminary communication.

285th ENMC international workshop: SMN-associated neurodevelopmental disorder: type 1 spinal muscular atrophy and the brain, 31st January - 2nd February 2025, Hoofddorp, The Netherlands.

285th ENMC international workshop: SMN-associated neurodevelopmental disorder: type 1 spinal muscular atrophy and the brain, 31st January - 2nd February 2025, Hoofddorp, The Netherlands.

Longitudinal assessment of respiratory status utilising the amended Great Ormond Street Respiratory Score in treated spinal muscular atrophy type 1 children.

Longitudinal assessment of respiratory status utilising the amended Great Ormond Street Respiratory Score in treated spinal muscular atrophy type 1 children.

Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.

Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.

Elexacaftor/Tezacaftor/Ivacaftor Therapy in a Child With Cystic Fibrosis and Type 1 Spinal Muscular Atrophy.

Elexacaftor/Tezacaftor/Ivacaftor Therapy in a Child With Cystic Fibrosis and Type 1 Spinal Muscular Atrophy.

Autism spectrum disorder in children with spinal muscular atrophy type 1: Case series.

Autism spectrum disorder in children with spinal muscular atrophy type 1: Case series.

A Retrospective Cohort Study of Nutrition Outcomes in Children With Spinal Muscular Atrophy Type 1 and 2 Treated With Disease Modifying Therapies.

A Retrospective Cohort Study of Nutrition Outcomes in Children With Spinal Muscular Atrophy Type 1 and 2 Treated With Disease Modifying Therapies.

Adult Survival in SMA Type 1: A 23-Year Journey With Home Ventilation and Multidisciplinary Support.

Adult Survival in SMA Type 1: A 23-Year Journey With Home Ventilation and Multidisciplinary Support.

Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye.

Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye.